Your cart

Your cart is empty

THIS CONTENT IS EXCLUSIVE TO SAGED MEMBERS.🔒

Please log in to your member account or sign up to view these contents in full.

Safety and Contraindications in Medical Cannabis
Safety and Contraindications in Medical Cannabis

Safety and Contraindications in Medical Cannabis

1 LEARNING CREDITS

    • Overview

      Medical cannabis use has expanded significantly in recent years,1 offering potential relief for many common conditions and symptoms such as chronic pain, nausea and vomiting, muscle spasms, sleep problems, epilepsy and some mental health conditions.2

      While medical cannabis is generally considered to be "well tolerated," health practitioners and professionals must still maintain up-to-date knowledge on key considerations, including:3,4

      • Legislative contraindications and safety advice
      • Potential adverse effects
      • Drug-to-drug interactions
      • Social and lifestyle impacts

      This module explores the safety profile and clinical contraindications of medical cannabis within the Australian healthcare setting. Designed for healthcare professionals, it covers key regulatory frameworks, TGA prescribing guidance, and access pathways. Learn to recognise when medical cannabis may be unsuitable, identify potential drug interactions, understand adverse effects, and address concerns such as cognitive impairment, dependence, and driving safety.

      By the end of this module, you'll be able to apply regulatory knowledge, assess patient suitability, and explain the physiological and behavioural effects associated with medical cannabis use.

      Preview this module by watching the video above.

      Estimated Duration: 1 hours

      Access Duration: 12 months from date of purchase

      Learning Outcomes

      Upon completion of this module, you’ll be able to:

      • Identify the primary regulatory bodies overseeing medical cannabis in Australia and explain their roles
      • Explain the origins and scope of the TGA's prescribing guidance documents
      • Describe the current status of medical cannabis products in Australia and identify the TGA's access pathways for unapproved goods
      • Identify conditions for which medical cannabis is contraindicated and associated risks
      • Recount TGA-recommended information to include in a clinical assessment
      • Discuss potential drug-drug interactions in medical cannabis treatment and their underlying mechanisms
      • Explain the safety profile of medical cannabis and potential side effects
      • Describe how THC may affect driving safety and summarise the resulting legislation and guidelines
      • Compare THC’s potential impact on driving with that of other substances
      • Describe cannabis' addictive potential and highlight relevant research gaps in this area
      • Detail the symptoms, mechanisms of action, and potential impacts of cannabis dependence and cannabis use disorder
      • Describe the symptoms of cannabis withdrawal and consider possible treatment options
      • Explain the potential cognitive effects of cannabis use

      References

      1. Australian Health Practitioner Regulation Agency. (2024, February 10). Australian Health Practitioner Regulation Agency - Regulators come together as one million Australians turn to medicinal cannabis treatments. Retrieved from www.ahpra.gov.au website: https://www.ahpra.gov.au/News/2024-02-20-medical-cannabis-treatment.aspx(Therapeutic Goods Administration, 2024)

      2. Therapeutic Goods Administration. (2024a, March 1). Medicinal cannabis: access pathways and usage data. Retrieved December 5, 2024, from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-usage-data#patient-access-via-the-special-access-scheme-sas-and-authorised-prescriber-ap-pathway

      3. Arnold, J. C. (2021). A primer on medicinal cannabis safety and potential adverse effects. Retrieved from Australian Journal of General Practice website: https://www1.racgp.org.au/ajgp/2021/june/a-primer-on-medicinal-cannabis-safety-and-potentiaTherapeutic Goods Administration, 2024b)

      4. Therapeutic Goods Administration. (2024b, November 28). Guidance for the use of medicinal cannabis in Australia: Overview. Retrieved from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/resources/resource/reference-material/guidance-use-medicinal-cannabis-australia-overview

    Overview

    Medical cannabis use has expanded significantly in recent years,1 offering potential relief for many common conditions and symptoms such as chronic pain, nausea and vomiting, muscle spasms, sleep problems, epilepsy and some mental health conditions.2

    While medical cannabis is generally considered to be "well tolerated," health practitioners and professionals must still maintain up-to-date knowledge on key considerations, including:3,4

    • Legislative contraindications and safety advice
    • Potential adverse effects
    • Drug-to-drug interactions
    • Social and lifestyle impacts

    This module explores the safety profile and clinical contraindications of medical cannabis within the Australian healthcare setting. Designed for healthcare professionals, it covers key regulatory frameworks, TGA prescribing guidance, and access pathways. Learn to recognise when medical cannabis may be unsuitable, identify potential drug interactions, understand adverse effects, and address concerns such as cognitive impairment, dependence, and driving safety.

    By the end of this module, you'll be able to apply regulatory knowledge, assess patient suitability, and explain the physiological and behavioural effects associated with medical cannabis use.

    Preview this module by watching the video above.

    Estimated Duration: 1 hours

    Access Duration: 12 months from date of purchase

    Learning Outcomes

    Upon completion of this module, you’ll be able to:

    • Identify the primary regulatory bodies overseeing medical cannabis in Australia and explain their roles
    • Explain the origins and scope of the TGA's prescribing guidance documents
    • Describe the current status of medical cannabis products in Australia and identify the TGA's access pathways for unapproved goods
    • Identify conditions for which medical cannabis is contraindicated and associated risks
    • Recount TGA-recommended information to include in a clinical assessment
    • Discuss potential drug-drug interactions in medical cannabis treatment and their underlying mechanisms
    • Explain the safety profile of medical cannabis and potential side effects
    • Describe how THC may affect driving safety and summarise the resulting legislation and guidelines
    • Compare THC’s potential impact on driving with that of other substances
    • Describe cannabis' addictive potential and highlight relevant research gaps in this area
    • Detail the symptoms, mechanisms of action, and potential impacts of cannabis dependence and cannabis use disorder
    • Describe the symptoms of cannabis withdrawal and consider possible treatment options
    • Explain the potential cognitive effects of cannabis use

    References

    1. Australian Health Practitioner Regulation Agency. (2024, February 10). Australian Health Practitioner Regulation Agency - Regulators come together as one million Australians turn to medicinal cannabis treatments. Retrieved from www.ahpra.gov.au website: https://www.ahpra.gov.au/News/2024-02-20-medical-cannabis-treatment.aspx(Therapeutic Goods Administration, 2024)

    2. Therapeutic Goods Administration. (2024a, March 1). Medicinal cannabis: access pathways and usage data. Retrieved December 5, 2024, from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-usage-data#patient-access-via-the-special-access-scheme-sas-and-authorised-prescriber-ap-pathway

    3. Arnold, J. C. (2021). A primer on medicinal cannabis safety and potential adverse effects. Retrieved from Australian Journal of General Practice website: https://www1.racgp.org.au/ajgp/2021/june/a-primer-on-medicinal-cannabis-safety-and-potentiaTherapeutic Goods Administration, 2024b)

    4. Therapeutic Goods Administration. (2024b, November 28). Guidance for the use of medicinal cannabis in Australia: Overview. Retrieved from Therapeutic Goods Administration (TGA) website: https://www.tga.gov.au/resources/resource/reference-material/guidance-use-medicinal-cannabis-australia-overview

    CONTENT EXCLUSIVE TO MEMBERS

    LOG IN OR SIGN UP